Magnus K Magnusson

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene
    Magnus K Magnusson
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 100:1088-91. 2002
  2. ncbi Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia
    M K Magnusson
    Hematology Branch, National Heart, Lung, and Blood Institute, and Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 98:2518-25. 2001
  3. ncbi Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner
    Ruth Seggewiss
    Hematology Branch, National Heart, Lung, and Blood Institute (NHLBI, the Immunology Laboratory, NIH/DHHS, Bldg 10, CRC, Rm 4-5140, 10 Center Dr, MSC 1202, Bethesda, MD 20892, USA
    Blood 105:2473-9. 2005

Collaborators

Detail Information

Publications3

  1. ncbi Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene
    Magnus K Magnusson
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 100:1088-91. 2002
    ..These results suggest that STI571 may be an effective targeted therapy in patients with CMML related to PDGFbetaR fusion oncogenes...
  2. ncbi Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia
    M K Magnusson
    Hematology Branch, National Heart, Lung, and Blood Institute, and Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 98:2518-25. 2001
    ..Early endosomal transport is critical in regulation of various growth factor receptors, through ligand-induced clathrin-mediated endocytosis, and thus this new fusion protein links together 2 important pathways of growth regulation...
  3. ncbi Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner
    Ruth Seggewiss
    Hematology Branch, National Heart, Lung, and Blood Institute (NHLBI, the Immunology Laboratory, NIH/DHHS, Bldg 10, CRC, Rm 4-5140, 10 Center Dr, MSC 1202, Bethesda, MD 20892, USA
    Blood 105:2473-9. 2005
    ....